Celltrion Allies With Rani As Exclusive Oral Ustekinumab Partner

Rani/Celltrion Suggest Potential To Broaden Partnership In Future

Having previously an agreement with BioFactura to assess the company’s proposed ustekinumab biosimilar with its RaniPill oral drug delivery technology, Rani has now unveiled a deal with Korean major Celltrion for use of its CT-P43 Stelara biosimilar candidate.

aorpixza/Shutterstock.com
• Source: Shutterstock

Celltrion will supply exclusively oral-dose biologics player Rani Therapeutics with its Stelara (ustekinumab) biosimilar drug substance for use in Rani’s proposed RT-111 orally administered ustekinumab biosimilar, in a partnership that the California-based biotech says validates its RaniPill oral drug delivery technology.

Under the firms’ license and supply agreement, Rani will be granted an exclusive license to use Celltrion’s CT-P43 ustekinumab biosimilar...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.